brain/
sourcestock-market

Autoresearch: WuXi AppTec v. DoD Answer after Sep 18; 2026 CDMO price series; TMO mix

Post-deadline docket recheck of 1:26-cv-02069 (ECF 29 Answer filed Sep 18); still no independent 2026 realized mAb fill-finish/CDMO price series; TMO Q2 does not isolate BIOSECURE/fill-finish and Q3 is unprinted.

Source

Autoresearch: WuXi AppTec v. DoD Answer after Sep 18; 2026 CDMO price series; TMO mix

Generated by /autoresearch on 2026-09-19. Synthesized across 3 rounds from 11 fetched web pages (1 timeout) plus a Grokipedia anchor. See Provenance. Treat as raw material — review before promoting into a project or thread. Context: vault/projects/stock-market Priors: skipped (user instruction).

Summary

DoD did file an Answer on the September 18, 2026 deadline. Live CourtListener docket 73471030 now lists ECF 29 as ANSWER to Complaint by the United States defendants (Jankowski), dated September 18, 2026, 5:34 p.m. EDT. That is not a further extension and is not titled as a dispositive motion. The Answer PDF is not yet in RECAP, so the pleading body is unread. Clearinghouse 48222, PACER Monitor, Law360, and the CourtListener search index still stop at ECF 28 — those mirrors are stale relative to the live docket. The August 7, 2026 preliminary injunction still bars enforcement of the 1260H designation. OMB’s biotechnology-companies-of-concern list is still due 18 December 2026.

No independent 2026 realized mAb fill-finish or CDMO contract-price series was found. Mordor’s −15% figure remains a 2023–2025 consultant claim. BioPlan’s April 2026 survey is capacity/utilization, not price. Fill-finish operators still do not publish unit prices. Step 3 of the Western-CDMO pricing-power chain stays unresolved. Do not silently downgrade or upgrade it.

Thermo Fisher’s Q2 2026 10-Q and 8-K Ex. 99.1 still do not name BIOSECURE or WuXi and do not isolate a fill-finish or BIOSECURE revenue-mix increment. Pharma services printed $1.893B (~15.8% of $11.994B); BioProduction $941M; Life Sciences Solutions organic +3%. Q3 2026 has not ended and is unprinted (street calendar October 15).

Findings

1. Docket after the September 18 deadline: Answer filed (ECF 29)

As of this 2026-09-19 recheck, the live CourtListener HTML for WUXI APPTEC CO., LTD. v. U.S. DEPARTMENT OF DEFENSE, D.D.C. 1:26-cv-02069, docket 73471030, reads:

  • Last Updated: Sept. 18, 2026, 6:36 p.m.
  • Date of Last Known Filing: Sept. 18, 2026
  • ECF 28 (Aug. 27, 2026): Consent motion extending the Answer-or-otherwise-respond deadline to September 18, 2026; granted by Chief Judge Boasberg the same day (CourtListener docket).
  • ECF 29 (Sep. 18, 2026): ANSWER to Complaint by MICHAEL CADENAZZI, STEVE FEINBERG, PETE HEGSETH, U.S. DEPARTMENT OF DEFENSE.(Jankowski, William) (CourtListener docket; document page ECF 29).

The document page timestamps the Answer at September 18th, 2026, 5:34 p.m. EDT and states: “This item is not yet in the RECAP collection” (ECF 29 page). No ECF 30, no further consent extension, and no docket line titled motion to dismiss / judgment on the pleadings appeared on the live docket HTML fetched this pass. Honest label: the government met the “Answer or otherwise respond” deadline with a paper captioned as an Answer. Whether that Answer embeds Rule 12 defenses in the body cannot be checked until RECAP (or PACER) yields the PDF.

Stale mirrors (do not treat as “no Answer”):

  • Clearinghouse case 48222 still ends at the Aug. 27 ECF 28 minute order. Its hosted-document table still tops out at the Aug. 7 PI order/opinion (ECF 24/25).
  • PACER Monitor’s public case page (65141636) likewise did not surface ECF 29 in the extract available this pass.
  • CourtListener’s search-index dump used in Round 1 still showed “Last Updated: Aug. 29, 2026” / “Date of Last Known Filing: Aug. 27, 2026”. The live page fetch is the source of truth; the index lagged by three weeks.
  • justice.gov search returned no WuXi / 1:26-cv-02069 Answer or dismissal notice (unrelated DOJ hits only).

What did not change:

  • Aug. 7, 2026 PI: Defendants “preliminarily ENJOINED from enforcing, implementing, or otherwise giving effect to” the 1260H designation; $1 bond (CourtListener docket; opinion also at govinfo USCOURTS-dcd-1_26-cv-02069 and RECAP ECF 25). AVIC / SASAC-stake ~0.001% remains the PI-era factual finding in the redacted reply (RECAP ECF 19) and the opinion’s arbitrary-and-capricious analysis. The PI was not dissolved by the Answer.
  • Case remains ongoing (Clearinghouse).

Calendar implication (honest, not a silent downgrade): filing an Answer keeps the APA case alive under the existing PI. It is not a new designation, not a lift of the injunction, and not an OMB BCOC listing. The BIOSECURE statutory clock is unchanged (below).

2. OMB BCOC list still due 2026-12-18

BIOSECURE became law on December 18, 2025 as § 851 of the FY2026 NDAA (Pub. L. 119-60) (Baker McKenzie, 19 Jan 2026). OMB must publish the initial biotechnology-companies-of-concern list within one year of enactment, by 18 December 2026 (K&L Gates, 20 Jan 2026). Baker McKenzie states the same outer bound as “December 2026” and then 180 days for OMB guidance and one year for FAR revision; 1260H entities’ prohibitions become effective 60 days after the FAR rewrite (Baker McKenzie). No fetched 2026-09 source moved that Dec. 18 date. The PI bars this 1260H designation’s enforcement; it does not, on the sources fetched here, rewrite the OMB list statute.

Grokipedia’s WuXi AppTec primer (3,017 chars, 131 citations; fetched 2026-09-19) correctly places WuXi under US national-security / BIOSECURE watchlist pressure but is encyclopedic and does not yet reflect the Aug. 7 PI or the Sep. 18 Answer. Treat it as vocabulary, not the docket.

3. No independent 2026 realized mAb fill-finish or CDMO price series

Verdict: none found. The Step 3 contradiction is not resolved and is not silently downgraded.

What this pass actually retrieved:

  • Mordor (consultant, not a realized tape). “Contract fill-finish pricing for monoclonal antibodies decreased by 15% from 2023 to 2025, reflecting increased capacity and intense bidding,” restated as “antibody fill-finish rates declined by another 15% between 2023 and 2025” (Mordor — Sterile Injectable Contract Manufacturing). That is the same 2023–2025 history already on the chain. Mordor’s separate fill-finish CM market page is a 2026–2031 size forecast ($6.43B in 2025 → $6.83B in 2026 → $9.21B by 2031) (Mordor — Fill Finish Pharmaceutical CM) — market-size modeling, not a 2026 transaction series.
  • BioPlan 23rd Annual Survey (April 2026) = capacity, not price. 49% of qualified respondents reported difficulty finding mammalian CDMO capacity in 2026, vs 41.3% in 2025 and 39% in 2024; CMO planned 5-year mammalian expansion 40.4% vs 33.8% in 2025 (Contract Pharma / BioPlan, 12 Aug 2026). Useful for the scarcity leg; it does not publish a $/vial or $/g realized series.
  • Operators still do not publish unit prices. “At an industry-aggregate level, no information regarding price-per-unit, price-per-batch, or margin figures specific to biologics fill-finish services are published by any fill-finish operators” (Towards Healthcare, North America Biologics Fill-Finish 2026).
  • Listed CDMO 2026 prints are revenue/margin, not ASP. Samsung Biologics Q2’26 KRW 1,321B revenue / KRW 586B OP (PR Newswire search hit; not re-fetched as a price series). Lonza H1’26 Integrated Biologics +10.0% CER, CORE EBITDA margin 36.0% — no vial ASP. SEC supply agreements located this pass (e.g. Vaxcyte–Lonza, Emergent) redact batch price.
  • Nice Insight / ISR 2026. ISR’s March 2026 Biologic Drug Product CDMO Benchmarking is sponsor-perception / cost-perception, paywalled, not a transaction tape (ISR 9th ed.). Nice Insight’s “State of the Industry 2026” search snippets mention consultant list/RFP comments (clinical sterile +20% since 2023; GLP-1-era fees “rising over 10% annually”; GMP batch list prices “relatively stable over 2024–2025”). That page timed out on fetch — do not treat those snippet figures as verified, and even if fetched they would remain consultant RFP/list commentary, not an independent realized 2026 mAb fill-finish series. PeptideStaff Q2 2026 “indicative” vial ranges are peptide-market estimates, not mAb realized.

Label for the chain: Step 3 (scarcity → Western CDMO pricing power) stays partial / contradiction unresolved. Mordor −15% (2023–2025, consultant) still sits against the claimed pricing-power leg. Twenty-six weekdays of “no 2026 realized series” as of the Sep. 18 morning check is unchanged through this Saturday (2026-09-19) recheck. Capacity-tightness evidence (BioPlan 2026) is compatible with either price-up or mix/lead-time rationing; it does not adjudicate the −15%.

4. TMO Q2/Q3 2026 does not isolate a BIOSECURE / fill-finish mix increment

Verdict: no. Q2 exists and is silent on BIOSECURE/WuXi. Q3 does not exist yet.

From the Q2 10-Q for the quarter ended June 27, 2026, filed July 31, 2026 (SEC tmo-20260627.htm):

LineQ2 2026Q2 2025Notes
Consolidated revenue$11,994M$10,855M
Pharma services$1,893M$1,794M+$99M; ~15.8% of Q2 2026 revenue; 2 ppts of LPBS reported growth
BioProduction$941M$745M+$196M reported in LSS commentary (includes 2025 filtration/separation deal)
LPBS segment$6,693M$5,995M+12% reported / +5% organic (6% M&A, 1% FX)
Life Sciences Solutions$2,815M$2,499M+13% reported / +3% organic (9% M&A, 1% FX)

String search of the 10-Q HTML for BIOSECURE, WuXi, Wu Xi, biosecure, Chinese military, and 1260H returned no matches (SEC 10-Q). The 10-Q does mention a 2025 acquisition of “a sterile fill finishing and packaging facility” inside LPBS and the Sep. 1, 2025 Solventum filtration/separation deal inside LSS — historical capacity, not a 2026 BIOSECURE mix line. Pharma-services growth is attributed to volume / “when we’re actually shipping,” not to a named BIOSECURE increment.

The Q2 8-K (July 23, 2026) Item 2.02 + Exhibit 99.1 (tmo-20260723.htm, q22026earnings8kex99_1.htm) likewise does not name BIOSECURE or WuXi (string search of Ex. 99.1: no hits). The IR release (Thermo Fisher Q2 2026 results) matches the 8-K totals and does not isolate fill-finish.

Q2 call color (secondary reprints, not a BIOSECURE line): management said Patheon / pharma services had “modest growth… in line with our expectations,” with 2H stronger on shipping phasing, and that the business “has benefited earlier in the year from a number of wins around reshoring that has been embedded in the outlook” (stockanalysis Q2 2026 transcript; Motley Fool Q2 2026 transcript). “Reshoring” ≠ a disclosed BIOSECURE / WuXi / fill-finish dollar increment. Do not upgrade Step 4 on that sentence.

Q3 2026: the fiscal quarter had not closed as of 2026-09-19. No Q3 10-Q or 8-K exists. RTTNews lists a Q3 print on October 15, 2026, BMO (RTTNews TMO calendar). Until that 10-Q/8-K, the July change-condition (“named BIOSECURE/WuXi mix increment”) remains unmet.

Contradictions and open questions

  • Answer body unread. ECF 29 is captioned Answer, 5:34 p.m. EDT Sep. 18, not in RECAP. A hidden 12(b) argument inside an Answer is possible and untestable from the docket line. Follow-up: refetch RECAP / PACER PDF; watch for ECF 30+.
  • Mirror lag. Clearinghouse, PACER Monitor, Law360, and the CourtListener search index still looked like “no Answer.” Live HTML is ahead. Any later pass that only hits those mirrors will falsely report a miss.
  • Mordor −15% (2023–2025) vs Western pricing-power claim. Still the same contradiction. 2026 realized series: none. BioPlan 2026 tightens the capacity picture without pricing. Do not adjudicate Step 3 from capacity-alone or from consultant forecasts.
  • Nice Insight 2026 snippets vs Mordor. If the timed-out Nice Insight page really says clinical sterile +20% since 2023, that would cut against Mordor’s mAb fill-finish −15% — but it is a different (clinical sterile / GLP-1) slice, consultant-sourced, and unfetched. Do not use it to “resolve” the contradiction.
  • TMO “reshoring wins” on the Q2 call are not a BIOSECURE increment and are not in the 10-Q/8-K. Q3 (print ~Oct 15) is the next issuer chance to isolate mix.
  • PI vs OMB clock. The PI blocks enforcement of this 1260H listing; OMB’s Dec. 18 BCOC list is a separate statutory duty. Whether OMB can or will list WuXi AppTec while the designation is enjoined is untested in the sources fetched here.

Provenance

Rounds run: 3 of 3 (full)

Sub-questions by round:

Round 1 (broad survey):

  1. Docket status after the Sep. 18, 2026 Answer deadline — Answer, further extension, or dispositive motion?
  2. Independent 2026 realized mAb fill-finish or CDMO contract-price series (not consultant forecasts)?
  3. Does TMO Q2 or Q3 2026 isolate a BIOSECURE / fill-finish revenue mix increment?
  4. Is the OMB BCOC list still due 2026-12-18, and did post-PI 1260H enforcement change?

Round 2 (drill-down):

  1. What did DoD’s Sep. 18 paper actually plead — Answer only, or also a dispositive motion? — targeting the newly visible ECF 29
  2. Any independent 2026 realized mAb fill-finish / sterile CDMO ASP (BioPlan, ISR, DCAT, Lonza/Samsung prints)? — targeting the Mordor −15% contradiction
  3. TMO Q3 calendar and any post-Q2 8-K that names BIOSECURE or isolates fill-finish? — targeting mix isolation

Round 3 (resolve remaining uncertainty):

  1. Any docket paper after ECF 29 (MTD, further extension) as of 2026-09-19? — targeting Answer-vs-dispositive-motion
  2. Does TMO Q2 8-K Ex. 99.1 name BIOSECURE / WuXi or isolate fill-finish? — targeting mix isolation
  3. Last pass: DCAT / ISR / Nice Insight 2026 realized mAb fill-finish prices? — targeting the still-open Mordor contradiction

Anchor source (Grokipedia, fetched before round 1):

  • WuXi AppTec — 3,017 chars extracted (131 citations; source: api; fetched 2026-09-19T20:39:42Z via _lib/grokipedia.py) — encyclopedic CRDMO / BIOSECURE-watchlist primer; does not cover the Aug. 7 PI or Sep. 18 Answer.

URLs fetched (11 successful, 1 failed):

Round 1:

Round 2:

Round 3:

Search-only / not treated as fetched primaries: PACER Monitor case page; Law360 case hub; Motley Fool and stockanalysis TMO Q2 transcripts (used only to locate the “reshoring” sentence, quoted as secondary); RTTNews TMO calendar; ISR 2026 benchmarking paywall page; PeptideStaff indicative peptide vial ranges; Samsung / Lonza earnings hits; Holland & Knight / Goodwin / Arnold Porter / FDA Law Blog 1260H explainers (calendar corroboration only; Dec. 18 cite is K&L Gates / Baker McKenzie). justice.gov returned no on-point WuXi filing.

Tools used: WebSearch, WebFetch, grokipedia-fetch (_lib/grokipedia.py). No --include-x. Generated: 2026-09-19 (UTC)

Chain-label reminder (do not silently downgrade): BIOSECURE-as-law and the Dec. 18 OMB list are intact. The Aug. 7 PI still enjoins this 1260H designation. DoD answered on time (ECF 29). Step 3 pricing-power vs Mordor −15% remains an unresolved contradiction — still no 2026 realized series. TMO Q2/Q3 still do not isolate a BIOSECURE / fill-finish mix increment. No buy / sell / size in this file.

Referenced by
Questions
Contradiction (not a new TMO thesis): Western CDMO pricing-power claim vs realized mAb fill-finish price action — and an unread WuXi Answer